Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
1.447
-0.003 (-0.23%)
Nov 4, 2024, 4:00 PM EST - Market closed

Barinthus Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Revenue
-0.844.70.274.826.85
Revenue Growth (YoY)
--98.21%16580.22%-94.44%-29.57%-
Cost of Revenue
43.9544.8742.3520.3714.3929.84
Gross Profit
-43.95-44.072.35-20.1-9.57-23
Selling, General & Admin
27.7239.796.4725.1210.482.67
Research & Development
-2.67-3.46-1.24-4-3.28-2.98
Operating Expenses
24.2636.335.2321.127.2-0.31
Operating Income
-68.21-80.4-2.87-41.22-16.77-22.69
Interest Expense
-0.04-0.03-0.02-2.67-3.6-0.13
Interest & Investment Income
2.182.883.10-0.04
Currency Exchange Gain (Loss)
---0.210.45-
Other Non Operating Income (Expenses)
0.791.080.576.332.080.08
EBT Excluding Unusual Items
-65.28-76.470.78-37.35-17.84-22.7
Gain (Loss) on Sale of Assets
-----0
Other Unusual Items
-0.06-0.060.07-13.79--
Pretax Income
-65.33-76.520.85-51.14-17.84-22.7
Income Tax Expense
-1.47-3.08-4.47-0.030.1-
Earnings From Continuing Operations
-63.86-73.455.32-51.11-17.93-22.7
Minority Interest in Earnings
0.080.10.020.250.231.97
Net Income
-63.79-73.355.34-50.87-17.71-20.73
Net Income to Common
-63.79-73.355.34-50.87-17.71-20.73
Shares Outstanding (Basic)
3938372680
Shares Outstanding (Diluted)
3938382680
Shares Change (YoY)
2.59%0.57%47.40%227.59%33580.72%-
EPS (Basic)
-1.65-1.910.14-1.96-2.24-883.28
EPS (Diluted)
-1.65-1.910.14-1.96-2.24-883.28
Free Cash Flow
-55.01-56.34-20.57-33.73-11.32-18.81
Free Cash Flow Per Share
-1.42-1.47-0.54-1.30-1.43-801.48
Gross Margin
--5.26%--198.42%-
Operating Margin
--10024.69%-6.43%-15380.60%-347.79%-331.46%
Profit Margin
--9145.51%11.95%-18979.48%-367.27%-302.84%
Free Cash Flow Margin
--7024.69%-46.01%-12585.45%-234.83%-274.80%
EBITDA
-65.6-78.17-1.75-40.82-16.56-22.52
EBITDA Margin
---3.92%---
D&A For EBITDA
2.612.231.120.40.210.17
EBIT
-68.21-80.4-2.87-41.22-16.77-22.69
EBIT Margin
---6.43%---
Revenue as Reported
-0.844.70.274.826.85
Source: S&P Capital IQ. Standard template. Financial Sources.